We have explored the use of adenovirusmediated gene transfer to transiently elicit production of low density lipoprotein (LDL) receptors in mice. A recombinant adenovirus carrying the human LDL receptor cDNA restored LDL receptor function in receptor-deficient cultured cells. Intravenous injection of recombinant virus acutely lowered plasma cholesterol levels and increased the rate of 12SI-labeled LDL clearance from the circulation in normal mice. At 4 days after virus injection, the t1/2 of plasma LDL was reduced up to 10-fold. An estimated 90% of the parenchymal cells in liver expressed the adenovirus-transferred genes as judged by immunofluorescence of LDL receptors or by P-galactosidase staining. These results demonstrate that adenovirus-mediated transfer of the LDL receptor gene provides an efficient way of augmenting LDL receptor gene function in the liver over the short term.
The abiilty to express genes acutely in the liver provides a powerful tool for the study of metabolism and genetic metabolic disorders in intact animals. One example of such a disorder is familial hypercholesterolemia, a frequent human genetic disease that is caused by mutations in the low density lipoprotein (LDL) receptor gene (1) (2) (3) (4) (5) . Several possible strategies to introduce the LDL receptor and other genes into cells in culture and into tissues in vivo have been used in the past (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . These experiments have included introduction of the LDL receptor gene into hepatocytes that were successfully returned to the liver (11) , and they have also included intravenous administration of a plasmid containing the LDL receptor gene (16) .
Recently, adenovirus-mediated gene transfer has been recognized to provide a means of high-efficiency gene transfer into a broad spectrum of eukaryotic cells (12, 17, 18) and into whole animals (6, 7, 19) . In a pioneering study, adenovirus-mediated gene transfer was used to cure a rare recessive genetic disorder, ornithine transcarbamylase deficiency, in newborn mice (6) . Enzymatic activity expressed from the transferred gene was sustained for up to 15 months. Similarly, the gene for human a1-antitrypsin has been introduced into the livers of normal rats by intraportal injection (20) .
In this study we have investigated the metabolic effect of adenovirus-mediated introduction of the human LDL receptor gene into the normal mouse liver. We have also assessed the efficiency of gene transfer in a quantitative way.
MATERIALS AND METHODS
Preparation of 125I-Labeled LDL (125ILDL). Human plasma LDL was prepared as described and iodinated by the iodomonochloride method (21) . Specific activities of 125I-LDL preparations were 200 and 550 cpm per ng of protein.
Preparation of Recombinant Adenovirus. Recombinant adenoviruses (22) containing the cDNA encoding the human LDL receptor (AdCMV-LDLR) (CMV, cytomegalovirus) (23), ,-galactosidase (AdCMV-(8Gal) (24) , and firefly luciferase (AdCMV-Luc) (25) were prepared essentially as described using cotransfection of pACCMVpLpA (26) and pJM17 (27) into 293 cells (28) .
Large Scale Preparation ofRecombinant Adenovirus. Large scale production of recombinant adenovirus was performed in 293 cells grown either in 15-cm culture dishes or in suspension using Joklik's calcium-free minimum essential medium (GIBCO) supplemented with 10% fetal calf serum. Infected cells were lysed 48 hr postinfection with Dulbecco's phosphate-buffered saline (PBS) (GIBCO) containing 1 mM MgCl2 and 0.1% Nonidet P-40. Virus-containing extracts were centrifuged at 12,000 x g for 10 min to remove debris before precipitation of the virus particles by addition of 0.5 vol of 20%o polyethylene glycol (PEG) 8000/2.5 M NaCl and incubation on ice for 1 hr. Virus was collected by centrifugation at 12,000 x g for 10 min, resuspended in isotonic saline (135 mM NaCI/5 mM KCl/1 mM MgCl2/10 mM Tris'HCl, pH 7.4), and dialyzed against the same buffer overnight before sterilization through a 0.22-,um filter. Alternatively, PEGprecipitated virus was further purified by CsCl density centrifugation essentially as described (29) . Equivalent results were obtained with both methods of preparing virus.
125I-LDL Degradation in ldlA7 Cells. Chinese hamster ovary (CHO) ldlA7 cells (30) in six-well dishes were infected with the indicated amount of recombinant virus at densities of 6 x 105 and 1.7 x 106 cells per well in 1 ml of Dulbecco's modified Eagle's medium (DMEM) containing 2% fetal calf serum. 125I-LDL (4 pg/ml) in DMEM without glutamine containing 0.2% bovine serum albumin was added to the cells 60 hr after infection and incubation was continued for 6 hr. The appearance of 125I-LDL degradation products in the medium was determined by measuring trichloroacetic acidsoluble radioactivity in the medium as described (21) .
Immunohistochemistry. Frozen liver sections were analyzed by immunocytochemistry using polyclonal (31) and monoclonal (32) antibodies as described (31 125I-LDL in 10 mM Tris'HCl/140 mM NaCl, pH 7.5, containing 0.2% bovine serum albumin was injected 4 days after virus administration into the opposite jugular vein or into a femoral vein. Blood (50-100 ,l) was obtained at the indicated intervals by retroorbital puncture from the anesthetized animals and collected into heparin-treated Pasteur pipettes. 125I-LDL levels in plasma were determined by measuring trichloroacetic acid-precipitable radioactivity of a 20-,ul plasma sample.
For determination of 125I-LDL uptake into the different tissues, animals were killed 20 min after injection of the label. Indicated organs were removed and homogenized in PBS, and radioactivity was determined in a sample of the homogenate.
Recombinant DNA Techniques and Protein Determinations. DNA manipulations were performed essentially as described in Sambrook et al. (33) . Protein concentrations were determined by the method of Lowry et al. (34) . Cholesterol concentrations were determined by the cholesterol oxidase method (Boehringer Mannheim).
RESULTS

Virally Transferred LDL Receptor Is Functional in Cultured
Cells. To quantify functional activity of AdCMV-LDLR, we determined the potency of the recombinant virus to confer the ability to degrade 125I-LDL on CHO cells that carry a defect in their endogenous LDL receptor gene (CHO ldlA7 cells) (30) . after infection with AdCMV-LDLR was also dependent on the amount of virus used to infect the cells (Fig. 1 Inset) .
To quantify the efficiency of adenovirus-mediated gene transfer to different tissues in vivo, we injected -2 x 109 pfu of AdCMV-Luc into the external jugular vein of five mice. Animals were sacrificed 4 days after the injection and luciferase activity was determined in the individual tissues ( Fig.  2A ). Low luciferase activity was detected in all of the tissues examined including skeletal muscle and heart, organs that had previously been shown to be target tissues for intravenously injected recombinant adenovirus (36) . However, >99% of the total enzyme activity recovered from the 1-3) or injected (lanes 4-6) with 2 x 109 pfu of AdCMV-LDLR. Four days after injection, the animals were sacrificed, and liver membranes prepared from each animal as described (35) were subjected to Western blotting (250 ,ug of protein per lane). Migration of the LDL receptor (LDLR) is indicated by the arrowhead. Total radioactivity present in each band was quantified by scanning the blot for 4 hr on an Ambis radioanalytic imaging system.injected mice was found in the liver. No luciferase activity was expressed in uninjected animals, which had uniform background levels regardless of the tissue examined (data not shown).
In Vivo Expression of Transferred Human LDL Receptor. To assess whether the recombinant virus was efficient in causing a physiologically relevant increase of LDL receptor activity in the liver, the primary site of lipoprotein catabolism (1), we injected three C57BL/6 female mice with t2 x 109 pfu of AdCMV-LDLR into the external jugular vein. Four days later, hepatic expression of the transferred LDL receptor was evaluated by Western blotting. Expression of LDL receptors in the livers of virus-injected animals was increased 10-fold over that observed in uninjected control mice (Fig. 2B) , assuming equal reactivity of the antibody with human and mouse receptors. Virus-injected animals also had significantly lower plasma cholesterol levels when compared with noninjected controls, indicating that the LDL receptor cDNA contained in the virus was transcribed and translated into biologically functional receptors. We next sought to determine the expression pattern of the virally transferred genes for human LDL receptor and E. coli f-galactosidase in the livers of injected mice. For this purpose, liver sections of animals that had been injected with either AdCMV-LDLR or AdCMV-I3Gal were examined by immunofluorescence analysis ( Fig. 3 A-D) or by histochemical staining for 3-galactosidase activity (Fig. 3 E and F) . LDL receptor was expressed only in the livers of animals that had been injected with AdCMV-LDLR (Fig. 3 A, B, and D) and was absent in animals that had been injected with AdCMV-f3Gal (Fig. 3C) .
Likewise, a similarly high percentage of liver cells of animals that had been injected with the adenovirus construct carrying the f-galactosidase gene were reactive upon histochemical examination for this enzyme (Fig. 3E) , while 3-galactosidase activity was completely absent from the livers of mice injected with AdCMV-LDLR (Fig. 3F) .
Increased Catabolic Rate of 1251-LDL. To further quantitate the effect of the virus-mediated transfer of exogenous LDL receptor cDNA, we examined the rate of 125I-LDL turnover and steady-state cholesterol levels in animals injected with Proc. Natl. Acad. Sci. USA 90 (1993) AdCMV-LDLR versus mice that had received AdCMV-/3Gal. Fig. 4 shows the results of four separate clearance studies performed with two different virus preparations. 125I-LDL was removed from plasma slowly by the control animals injected with AdCMV-PGal and the clearance rate (til1, -5 hr) was indistinguishable from that previously observed in normal mice (38) . In contrast, AdCMV-LDLR significantly accelerated removal of the radiolabeled ligand from the circulation of the animals. As a rule, the animals that cleared the 1251-labeled ligand most efficiently also had the lowest steady-state plasma cholesterol levels 4 days after virus administration (Fig. 4 and Table 1 ). The rate of 125I-LDL clearance was dose dependent and proportional to the amount of pfu of AdCMV-LDLR that had been injected into the mice and was up to 10-fold greater than the rate observed in either normal (38) or AdCMV-/3Gal-injected animals (this study).
The liver was the only organ in AdCMV-LDLR-injected mice that showed a significant increase in 125I-LDL radioactivity versus control animals when the absolute tissue uptake of the labeled ligand was measured 20 min after injection (Table 1 ). Up to 45% ofthe injected dose was recovered in the livers of AdCMV-LDLR-injected mice compared to 13-15% that had accumulated in the controls. Thus, even without compensating for nonspecific trapping of the tracer, significantly more 125I-LDL was taken up into the livers of AdCMV-LDLR-injected animals, in agreement with the results obtained for AdCMV-Luc (Fig. 2A) .
DISCUSSION
We have explored the feasibility of using replicationdefective adenovirus particles to transfer the LDL receptor gene into the liver. were infected with the recombinant virus and efficiently expressed foreign genes were harbored within the adenovirus genome. Expression of the human LDL receptor gene resulted in plasma cholesterol levels that were lower than those measured in animals that had been injected with a virus carrying the (3-galactosidase gene. Likewise, clearance of 125I-LDL from the circulation was up to 10-fold accelerated in mice injected with AdCMV-LDLR. This is consistent with the -10-fold increase of LDL receptor immunoreactivity in the livers of injected mice. Adenovirus-mediated gene transfer therefore can provide strong transient expression of an exogenous LDL receptor gene in the liver, predominantly in the hepatocytes. The liver is the primary target after peripheral intravenous injection of recombinant adenovirus as shown quantitatively in this study and was previously observed by Stratford-Perricaudet et al. (36) .
We have not yet explored other important questions that are essential to evaluate the potential suitability of the adenovirus system for the treatment of familial hypercholesterolemia or other inborn errors of metabolism that manifest themselves in the liver. These include the choice of the promoter driving the exogenous gene, safety concerns connected with the use of a human virus (20) , and the efficiency of virus-mediated gene transfer in patients or animals expressing neutralizing antibodies to adenovirus. It is also currently not clear for how long the adenovirus genome will persist in various tissues and whether persistence of gene expression will be longer in tissues that turn over slowly versus those that regenerate more rapidly (35) .
A pathological pneumonia-like response after intranasal inoculation of mice with type 5 adenovirus independent of viral replication has been reported (40) . In our study, we have also observed variable degrees of lymphocytic infiltrations in the livers of virus-injected mice (data not shown). The extent of the inflammatory reaction appeared to be proportional to the amount of administered virus and was paralleled by an increase ofliver marker enzymes in the plasma. To assess the potential therapeutic use of adenoviral LDL receptor gene transfer into the liver, further investigation of cytotoxic side effects caused by the virus will be required.
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